Table 1:

Key cancer therapeutics that target the mitochondrial unfolded protein response (UPR^mt)

UPRmt Target	Drug	Mechanism	Phase	References
HSP60	Epolactaene and derivatives	Inhibits HSP60/HSP10 chaperone activity	Preclinical	[7]
HSP60	Gold (III) porphyrins	Inhibits HSP60/HSP10 chaperone activity	Preclinical	[8]
HSP60	BSP-SCA hybrid analogs	Inhibits HSP60/HSP10 chaperone activity	Preclinical	[9]
mtHSP70	MKT 077	Inhibits interactions between mtHSP70 and Bag co-chaperones	Phase 1	[10]
mtHSP70	JG-231	Inhibits interactions between mtHSP70 and nucleotide exchange factors	Preclinical	[11]
LONP1	CDDO-Me	Inhibits LONP1 protease activity	Phase 1	[12,I*]
ClpP	ONC201	Hyperactivates ClpP protease activity	Phase 1,2	[IV*]
ClpP	A2-32-01	Inhibits ClpP protease activity	Preclinical	[13]
ATF5, CEBPs	(d/n)-ATF5 peptides	Prevents dimerization of transcription factors	Preclinical	[14]

^*Indicates references from ClinicalTrials.gov